Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Business Wire
- Enrollment complete in VRDN-003’s phase 3 clinical trials in thyroid eye disease (TED), REVEAL-1 and REVEAL-2, with each study exceeding its enrollment target due to strong patient demand; topline data on track for first half of 2026 -- VRDN-003 composition of matter patent granted by the USPTO with term to 2041 and potential to extend exclusivity -- Veligrotug Biologics License Application (BLA) submission on track and anticipated in November 2025, enabling a mid-2026 commercial launch, if approved under Priority Review -- VRDN-006 data in ongoing healthy volunteer study shows IgG reductions consistent with the FcRn inhibitor class and sparing of albumin and LDL; half-life extended VRDN-008 IND submission on track for year-end 2025 - WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that enrollm
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) was given a new $41.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.MarketBeat
VRDN
Earnings
- 2/27/25 - Beat
VRDN
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- VRDN's page on the SEC website